Showing 161 - 180 results of 14,940 for search '(( significantly increased decrease ) OR ( significance ((greatest decrease) OR (we decrease)) ))', query time: 0.49s Refine Results
  1. 161
  2. 162
  3. 163
  4. 164
  5. 165
  6. 166
  7. 167

    Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  8. 168

    Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  9. 169

    Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  10. 170
  11. 171
  12. 172

    S8 File - by Martha R. Smith (20410184)

    Published 2024
    Subjects:
  13. 173
  14. 174
  15. 175
  16. 176

    S9 File - by Martha R. Smith (20410184)

    Published 2024
    Subjects:
  17. 177

    S7 File - by Martha R. Smith (20410184)

    Published 2024
    Subjects:
  18. 178
  19. 179
  20. 180